Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

NCT05557292 is registered in ClinicalTrials.gov with Nicholas Butowski as lead sponsor.

NCT NCT05557292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05557292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Lead sponsor
Nicholas Butowski
Phase
Phase 1
Overall status
Terminated
Start date
April 3, 2023
Completion date
December 31, 2025
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, recurrent glioblastoma